Salem-News.com Heath articles

7 Ways To Deal With A Complicated Custody Battle

You must head into court with a sound action plan.

(SALEM, Ore.) - A child custody dispute can be one of the most traumatic things a parent can go through, particularly if you do not know what to expect.

Parents battling for custody of their children are plunged into a perilous legal quagmire while facing the horror of losing their children.

Standing up to the FEDS About Vaccines

CDC made a mockery of the Nuremberg code's directive that people must have "informed consent" when it refused to answer FOIA questions from a doctor whose son was autistic about the CDC's knowledge about mercury in vaccines and any discussions at the CDC about it.

(WASHINGTON DC) - While alternative media is exposing so much of what the genocidal Cabal is doing, trying to start more wars, trying to grab land a la Agenda 21, rigging Wall Street, rigging the entire banking system and Comex, and since the Cabal has more in store, including (more) fake pandemics, it seems just the right time to expose their vaccines.

Right now the vaccine debate is erroneously stuck ...

A Voice of Sanity About Childhood Vaccines from a Respected Nephrologist

It is ironic, but telling, to note that a few years ago there was a $10,000 award offered to any physician who would be willing to swallow the contents of what they freely inject into their unsuspecting patients.

(DULUTH, MN) - To my medical colleagues, BigPharma sceptics and others truly concerned with public health issues and the accelerating sickening of America:

In the following link, Dr. Suzanne Humphries talks about vaccines in a 10 minute videointerview justifiably, with science backing her up (and directly refuting what those corporate entities who have immense wealth and power), claiming that there has never been a safe vaccine.

Enrollment of the First Patient in the MF 1001 Glioblastoma Study at the Muenster University Clinic

The new MF 1001 glioblastoma study is designed to validate the results generated with NanoTherm(R) therapy to date by means of a direct comparison with established radiotherapy in a large patient population.

(BERLIN ) - MagForce AG (Frankfurt, Xetra: MF6), a leading medical technology company in the area of nanotechnology which focuses on oncology, today announced the enrollment of the first patient in the MF 1001 clinical study.

MF 1001 is an open-label, randomized, controlled clinical trial assessing the efficacy and safety of NanoTherm(R) therapy as monotherapy and in combination with radiotherapy compared to radiotherapy alone in glioblastoma patients at first relapse.